Previous 10 | Next 10 |
BEDMINSTER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced ...
- Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022 - - Company’s P roposal to S tockholders I ntende...
The following slide deck was published by Matinas BioPharma Holdings, Inc. in conjunction with this event. For further details see: Matinas BioPharma Holdings (MTNB) Investor Presentation - Slideshow
BEDMINSTER, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced ...
Are These On Your List Of Penny Stocks To Watch For December 2020? The month of November has already shown itself to be quite good for penny stocks . During the past few weeks, many popular stocks under $5 have shot up in value. This, of course, is not across the board, but there ar...
Matinas BioPharma (MTNB) has been awarded up to $3.75M from the Cystic Fibrosis Foundation ((CFF)) to support preclinical development of MAT2501, company's lipid nano-crystal oral formulation of aminoglycoside amikacin to treat nontuberculous mycobacterial ((NTM)) lung disease, including infe...
BEDMINSTER, N.J., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced ...
BEDMINSTER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, has been invited...
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2020 Results Conference Call November 06, 2020 08:30 AM ET Company Participants Peter Vozzo - IR Jerry Jabbour - CEO Keith Kucinski - CFO Dr. James Ferguson - Chief Medical Officer Conference Call Participants Bert Hazlett - BTIG Yasmeen Rahimi - Pip...
EnACT study of MAT2203 in cryptococcal meningitis received unanimous D ata and Safety Monitoring Board (DSMB) recommendation to pro ceed into second patient cohort – ENHANCE-IT s tudy of MAT9001 against Vascepa ...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...